Eye-Opening Insights on Ophthalmic Drug Development

Our Commitment to Better Vision
and Eye Health

With a deep understanding of the unique challenges presented by ocular drug development, Altasciences combines cutting-edge research, advanced technological platforms, and comprehensive regulatory expertise to support your program from lead candidate selection to market.

Our end-to-end ophthalmic expertise includes:

    •   50 years of experience with all ophthalmic therapeutic indications—no study ever rejected for reasons of design, conduct, or data integrity;

    •   all ophthalmic routes of administration and specialized techniques;

    •   many different types of formulations, including nanoparticles and ocular implants;

    •   ocular studies performed in multiple species (rodent and non-rodent);

    •   more than 40 ophthalmology clinical trials conducted;

    •   on-site Diplomate, American College of Veterinary Ophthalmologists (DACVO);

    •   significant investment in specialized equipment like optical coherence tomography (OCT) and RetCam; and

    •   state-of-the-art bioanalytical instrumentation and assay platforms.

Ready to dive deeper? Explore our full range of integrated CRO/CDMO ophthalmic drug development services and how they can accelerate your timeline by up to 40%.

Do you have an ocular drug compound in your development pipeline?
Speak with one of our experts about your study and let’s get you started!

Related resources that may interest you:

Webinar: Gene and Cell Therapy―Enhanced CNS and Ocular Delivery in NHPs
Fact Sheet: Our Comprehensive Ophthalmic Drug Development Services
Scientific Journal: The Complexities of Early Phase Ophthalmic Drug ​​​Development